Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Glimpse Group, Inc. Director's Dealing 2024

Mar 5, 2024

34791_dirs_2024-03-05_932d38b7-4fb7-4434-b585-2e8656b9ef89.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Glimpse Group, Inc. (VRAR)
CIK: 0001854445
Period of Report: 2024-02-29

Reporting Person: Charles Ian Morgan (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-02-29 Stock Option (Right to Purchase) $ D 30560 Disposed Common Stock (30560) Direct
2024-03-01 Stock Option (Right to Purchase) $2.50 A 20475 Acquired 2031-03-01 Common Stock (20475) Direct
2024-03-01 Stock Option (Right to Purchase) $2.50 A 24000 Acquired 2034-03-01 Common Stock (24000) Direct

Footnotes

F1: Represents the forfeiture, by Mr. Charles, of fully vested options to purchase an aggregate of 30,560 shares of the issuer's common stock granted under the issuer's 2016 equity incentive plan, as amended (the "2016 Plan"), consisting of (i) options to purchase 10,560 shares of the issuer's common stock granted to Mr. Charles on January 13, 2022 with an exercise price of $10.09 per share, and (ii) options to purchase 20,000 shares of the issuer's common stock granted to Mr. Charles on February 27, 2023 with an exercise price of $5.00 per share. The foregoing options were to expire 10 years from their respective grant dates.

F2: Mr. Charles was granted options to purchase 20,475 shares of the issuer's common stock under the 2016 Plan on March 1, 2023, which options became exercisable upon grant with an exercise price of $2.50 per share. These options are set to expire seven years from grant date.

F3: Represents options to purchase 24,000 shares of the issuer's common stock granted to Mr. Charles on March 1, 2024, as director compensation for calendar year 2024. The options vest monthly in arrears, retroactive to January 1, 2024 with an exercise price of $2.50 per share. These options are set to expire 10 years from grant date.